We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 43

How to minimize FCPA risk in health care acquisitions

  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • -
  • USA
  • -
  • May 10 2013

When acquiring a health care company doing business abroad, there is no such thing as being too thorough with anti-corruption due diligence. The

Three important lessons from the FCPA guidance for pharmaceutical and medical device companies

  • LeClairRyan
  • -
  • USA
  • -
  • December 4 2012

The US Chamber of Commerce “praised” the FCPA Guidance

Medical device company settlement highlights internal audit failures

  • Jenner & Block
  • -
  • USA
  • -
  • April 30 2012

Biomet Inc., a medical device company based in Indiana, has settled FCPA enforcement actions with the DOJ and SEC in connection with alleged improper payments by its subsidiaries and distributors to public doctors in Argentina, Brazil, and China

Recent insider trading case sparks concerns over leaked clinical trial results

  • Choate Hall & Stewart LLP
  • -
  • USA
  • -
  • December 20 2012

The Martoma insider trading case is the latest in, and largest of, a string of actions brought by the Securities and Exchange Commission related to the alleged misuse of confidential clinical trial information by life sciences companies and third parties with access to this information

Publicly traded life sciences companies in the United States Remain an increasingly popular target of securities fraud class action lawsuits

  • Dechert LLP
  • -
  • USA
  • -
  • March 21 2013

The past year was particularly noteworthy with respect to the absolute and relative number of securities fraud class action lawsuits brought against

FCPA liability in M&A: lessons from Pfizer settlements

  • Steptoe & Johnson LLP
  • -
  • USA
  • -
  • September 11 2012

On Aug. 7, 2012, the U.S. Department of Justice announced an enforcement action against Pfizer H.C.P. Corporation (Pfizer HCP), a wholly owned subsidiary of Pfizer Inc. (Pfizer), while the U.S. Securities and Exchange Commission announced related enforcement actions against Pfizer and Wyeth LLC, another wholly owned Pfizer subsidiary

Biomet Inc.

  • Dorsey & Whitney LLP
  • -
  • USA
  • -
  • April 16 2012

Medical device company Biomet has agreed to pay more than $22 million to settle charges by the Securities and Exchange Commission (SEC) as well as parallel criminal charges by the U.S. Department of Justice (DOJ

Continuing the trend: medical device maker Biomet settles FCPA charges for more than $22 million

  • Sheppard Mullin Richter & Hampton LLP
  • -
  • USA
  • -
  • April 5 2012

On March 26, 2012, U.S. medical device maker Biomet, Inc. (Biomet) agreed with the U.S. Department of Justice (DOJ) and U.S. Securities and Exchange Commission (SEC) to settle charges related to alleged bribes paid to obtain business in Argentina, Brazil, and China

Denial of leave to amend securities complaint affirmed on basis of futility

  • Katten Muchin Rosenman LLP
  • -
  • USA
  • -
  • March 28 2008

The Court of Appeals for the Eighth Circuit affirmed a decision dismissing Plaintiff’s class action securities fraud complaint and denying Plaintiff leave to amend

Supreme Court grants cert to determine if plaintiff must prove materiality before certifying class in securities fraud class action

  • Porter Wright Morris & Arthur LLP
  • -
  • USA
  • -
  • June 12 2012

On Monday, June 11, 2012, the Supreme Court granted a Writ of Certiorari in Amgen, Inc. v. Connecticut Retirement Plans and Trust Funds, No. 11-1085 (U.S. Jun. 11, 2012) to decide whether, in a misrepresentation case under SEC Rule l0b-5, the court must require proof of materiality before certifying a plaintiff class based on the fraud-on-the-market theory (and whether the court must allow the defendants to present evidence rebutting the applicability of the fraud-on-the-market theory before certifying the class

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy